I now have comprehensive data to synthesize a detailed comparison. Here it is:
Pregabalin vs Gabapentin vs Nortriptyline
All three are first-line agents for neuropathic pain, acting via different mechanisms. They can be used as monotherapy or combined.
Mechanism of Action
| Drug | Mechanism |
|---|
| Gabapentin | Binds α₂-δ subunit of voltage-gated calcium channels in the dorsal horn → ↓ release of glutamate and substance P |
| Pregabalin | Same mechanism as gabapentin (GABA analog, α₂-δ ligand); also has anxiolytic activity |
| Nortriptyline | Tricyclic antidepressant (TCA); inhibits norepinephrine > serotonin reuptake; also blocks sodium channels and NMDA receptors |
Pharmacokinetics
| Gabapentin | Pregabalin | Nortriptyline |
|---|
| Absorption | Non-linear; bioavailability decreases as dose increases (saturable transport) | Linear, predictable absorption — more consistent therapeutic range | Well-absorbed orally; extensive first-pass metabolism |
| Protein binding | Minimal | Minimal (not protein bound) | ~93% |
| Metabolism | Not hepatically metabolised; excreted unchanged renally | ~95% excreted unchanged in urine | Hepatic (CYP2D6) |
| Half-life | ~5–7 hours | ~6 hours | ~18–44 hours (once-daily dosing possible) |
| Renal dose adjustment | Yes — mandatory in CKD | Yes — mandatory in CKD | Not needed (hepatic) |
Key PK advantage of pregabalin: its linear pharmacokinetics means dose titration is more predictable than gabapentin, which has up to 50% bioavailability variation between individuals. — Barash Clinical Anesthesia, 9e
Dosing
| Drug | Typical Dose Range | Regimen |
|---|
| Gabapentin | 900–3,600 mg/day | TID (three divided doses) |
| Gabapentin XR | 1,200–3,600 mg/day | OD–BID |
| Pregabalin | 300–600 mg/day | BID |
| Nortriptyline | 25–150 mg/day | Usually OD (at night) |
Start low and titrate: gabapentin at 100–300 mg at bedtime; nortriptyline at 10–25 mg OD at night, especially in elderly.
Efficacy
- Pregabalin achieves an NNT of 2.2 for diabetic neuropathy (at 300 mg/day, ~45% of patients achieve ≥50% pain relief). Head-to-head evidence and clinical experience suggest pregabalin > gabapentin for neuropathic pain overall. — Bradley & Daroff's Neurology
- Gabapentin is the most extensively studied; recommended first-line particularly in the medically ill and elderly due to its safety profile and few drug–drug interactions.
- Nortriptyline (and other TCAs) are more versatile — effective for neuropathic pain, headache, nocipластic pain, and musculoskeletal disorders. However, they carry more adverse effects than gabapentinoids and are preferrable over amitriptyline due to a better side-effect profile.
- Gabapentinoids may be superior to antidepressants for lancinating/electrical-type pain specifically; antidepressants are more broadly applicable across pain types. — Goldman-Cecil Medicine
FDA-Approved Indications
| Condition | Gabapentin | Pregabalin | Nortriptyline |
|---|
| Postherpetic neuralgia (PHN) | ✓ | ✓ | Off-label |
| Diabetic peripheral neuropathy (DPN) | Off-label | ✓ | Off-label |
| Fibromyalgia | Off-label | ✓ | Off-label |
| Partial seizures | ✓ | ✓ | — |
| Spinal cord injury pain | Off-label | ✓ | — |
| Depression | — | — | ✓ |
Adverse Effects
| Gabapentin | Pregabalin | Nortriptyline |
|---|
| Drowsiness/sedation | ✓✓ | ✓✓ | ✓✓ |
| Dizziness/unsteadiness | ✓✓ | ✓✓ | ✓ |
| Dry mouth | ✓ | ✓ | ✓✓✓ (anticholinergic) |
| Peripheral oedema | ✓ | ✓✓ | — |
| Weight gain | ✓ | ✓✓ | ✓ |
| Cognitive/confusion | ✓✓ (elderly) | ✓ | ✓✓ |
| Constipation/urinary retention | — | — | ✓✓ (anticholinergic) |
| Cardiac (QTc prolongation) | — | — | ✓ (ECG monitoring recommended) |
| Overdose risk with opioids | ✓✓ | ✓✓ | ✓ |
Important warning: Both gabapentin and pregabalin significantly increase overdose risk when co-prescribed with opioids. — Barash Clinical Anesthesia, 9e
Nortriptyline vs amitriptyline: Nortriptyline is preferred over amitriptyline as a first-choice TCA because it has fewer anticholinergic side effects. — Goldman-Cecil Medicine
Combination Therapy
Combining agents from different classes provides superior analgesia over monotherapy:
- Gabapentin + nortriptyline → superior to either alone (landmark Lancet 2009 RCT)
- Gabapentin + morphine → better than either alone
- Nortriptyline + morphine → better than either alone
- Pregabalin + mirtazapine → superior to either alone
— Goldman-Cecil Medicine
When to Choose Each
| Scenario | Preferred Agent |
|---|
| Lancinating/electrical neuropathic pain | Pregabalin or gabapentin |
| Broad neuropathic pain with comorbid depression | Nortriptyline (TCA) or duloxetine |
| Elderly, medically ill, polypharmacy concern | Gabapentin (fewest drug interactions) |
| Need predictable dose titration | Pregabalin |
| Cost considerations | Gabapentin (generic, cheap) |
| Fibromyalgia (with FDA label) | Pregabalin |
| Postherpetic neuralgia | Gabapentin or pregabalin first-line |
| Concurrent anxiety disorder | Pregabalin (FDA-approved in some regions for GAD) |
| Cardiac risk / QTc concerns | Avoid nortriptyline; use gabapentinoid |
| Renal failure | Both gabapentinoids need dose adjustment; nortriptyline safer |
Summary
All three are first-line for neuropathic pain. Pregabalin has the edge in pharmacokinetic predictability and NNT data. Gabapentin is better studied, safer in frail/elderly patients, and cheaper. Nortriptyline is preferred when broader indications are needed (depression, headache, nocipластic pain) and offers once-daily dosing, but its anticholinergic burden and cardiac effects limit use in older patients. Combining gabapentin + nortriptyline is well-evidenced when monotherapy fails.
Sources: Bradley & Daroff's Neurology in Clinical Practice; Goldman-Cecil Medicine; Barash Clinical Anesthesia 9e; Harrison's Principles of Internal Medicine 22e; Morgan & Mikhail's Clinical Anesthesiology 7e